Skip to main content
SSY Group Limited logo

SSY Group Limited — Investor Relations & Filings

Ticker · 2005 ISIN · KYG8406X1034 HKEX Manufacturing
Open in API
Filings indexed 1,213 across all filing types
Latest filing 2024-12-27 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2005

About SSY Group Limited

http://www.ssygroup.com.hk

SSY Group Limited is an investment holding company specializing in the research, development, manufacturing, and sale of pharmaceutical products. The Group is a prominent manufacturer, with a core focus on producing a wide range of intravenous infusion solutions and finished drugs. Complementing its pharmaceutical offerings, the company also manufactures essential packaging materials, including non-PVC soft bags and PP plastic containers. SSY Group supplies its comprehensive product line, which often utilizes green production technologies aimed at reducing costs and power consumption, primarily to hospitals and medical institutions.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - UPDATE ON PRODUCT DEVELOPMENT
Regulatory Filings Classification · 85% confidence The document is a short voluntary business update announcement by a Hong Kong–listed company regarding product development approvals. It does not present financial results (so not ER, IR, 10-K, or IR), no AGM materials, no management change, no dividend notice, no share issue or capital change, no voting results or M&A, nor a report publication. It simply informs investors of operational developments. Therefore it falls into the fallback category for general regulatory/voluntary announcements: RNS.
2024-12-27 English
VOLUNTARY ANNOUNCEMENT - UPDATE ON PRODUCT DEVELOPMENT
Regulatory Filings Classification · 85% confidence The document is a Hong Kong Stock Exchange announcement titled “Voluntary Announcement Update on Product Development.” It provides business development information (approval of a drug’s consistency evaluation) rather than financial results, management changes, or a formal report. It does not fit any specific category such as earnings release, interim report, or M&A. Therefore, it falls into the fallback category for miscellaneous regulatory announcements (Regulatory Filings).
2024-12-27 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 90% confidence The document is an HKEX Form FF305 “Next Day Disclosure Return” detailing changes in issued and treasury shares, specifically disclosing a share repurchase (on‐market buyback) of 746,000 ordinary shares with prices and totals provided. This matches our “Transaction in Own Shares” category for share repurchases/sales of treasury shares.
2024-12-20 English
BUSINESS UPDATE - FRAMEWORK AGREEMENT WITH HIGHTIDE THERAPEUTICS, INC. FOR JOINT RESEARCH AND DEVELOPMENT
Regulatory Filings Classification · 81% confidence The document is a voluntary business update announcement by SSY Group Limited regarding entering a framework cooperation agreement with HighTide Therapeutics. It contains no financial results, no call transcript, no share issue, no M&A takeover, no dividend or voting details, and is simply a regulatory announcement of a strategic cooperation. It does not meet any specialized category, so the appropriate fallback is Regulatory Filings (RNS).
2024-12-19 English
CONTINUING CONNECTED TRANSACTIONS - (1) MASTER SALE AND PURCHASE AGREEMENT AND (2) MASTER PRODUCTS MANUFACTURING AND TRANSPORTATION SERVICES AGREEMENT
Regulatory Filings Classification · 80% confidence The document is a Hong Kong Stock Exchange announcement detailing the renewal of master sale and purchase and manufacturing/transport services agreements with a connected person under Chapter 14A of the Listing Rules. It does not present full financial statements (Annual or Interim Report), it is not an earnings release, capital raise, or share issue, nor is it a management discussion or legal proceeding. It is an ongoing connected‐party transaction disclosure required by the exchange. As no more specific category matches, it falls into the fallback “Regulatory Filings” category (RNS).
2024-12-19 English
VOLUNTARY ANNOUNCEMENT - UPDATE ON PRODUCT DEVELOPMENT
Regulatory Filings Classification · 85% confidence The document is a short voluntary corporate announcement on product development (regulatory approvals for drug registration) published on the Hong Kong Stock Exchange. It is under 5,000 characters, contains no financial statements or detailed report content, and merely informs shareholders of business updates. This fits the generic Regulatory Filings (RNS) category as a fallback for miscellaneous announcements.
2024-12-16 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.